Eisai Inc., a subsidiary of Tokyo-based Eisai Co., Ltd., today announced the sale and assignment of its rights to a worldwide exclusive license for DACOGEN® (decitabine) for Injection to Otsuka Pharmaceutical Co., Ltd., giving Otsuka full development and commercialization rights for the product in the former Eisai territories of the United States, Canada and Japan. Eisai will retain its rights for DACOGEN® in Mexico.
In addition, Eisai Inc. has assigned the patent right for its metabolic enzyme inhibitor E7727 to Otsuka.
Eisai's marketing rights for DACOGEN® flow from a worldwide license from Astex Pharmaceuticals, Inc., which was acquired by Otsuka in October 2013.